197 related articles for article (PubMed ID: 8347500)
1. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of bryostatin 1 in metastatic malignant melanoma.
Propper DJ; Macaulay V; O'Byrne KJ; Braybrooke JP; Wilner SM; Ganesan TS; Talbot DC; Harris AL
Br J Cancer; 1998 Nov; 78(10):1337-41. PubMed ID: 9823975
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Tozer RG; Burdette-Radoux S; Berlanger K; Davis ML; Lohmann RC; Rusthoven JR; Wainman N; Zee B; Seymour L;
Invest New Drugs; 2002 Nov; 20(4):407-12. PubMed ID: 12448658
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
12. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of bryostatin 1 and gemcitabine.
El-Rayes BF; Gadgeel S; Shields AF; Manza S; Lorusso P; Philip PA
Clin Cancer Res; 2006 Dec; 12(23):7059-62. PubMed ID: 17145828
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
Clamp AR; Blackhall FH; Vasey P; Soukop M; Coleman R; Halbert G; Robson L; Jayson GC;
Br J Cancer; 2003 Oct; 89(7):1152-4. PubMed ID: 14520436
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.
Armstrong DK; Blessing JA; Look KY; Schilder R; Nunez ER
Invest New Drugs; 2003 Aug; 21(3):373-7. PubMed ID: 14578687
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
[TBL] [Abstract][Full Text] [Related]
18. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.
Madhusudan S; Protheroe A; Propper D; Han C; Corrie P; Earl H; Hancock B; Vasey P; Turner A; Balkwill F; Hoare S; Harris AL
Br J Cancer; 2003 Oct; 89(8):1418-22. PubMed ID: 14562010
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
20. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.
Brockstein B; Samuels B; Humerickhouse R; Arietta R; Fishkin P; Wade J; Sosman J; Vokes EE
Invest New Drugs; 2001; 19(3):249-54. PubMed ID: 11561683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
